Breaking News
Get 50% Off 0
📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-Earnings Read more
Close

Incyte Corporation (INCY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Incyte's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
65.87 +0.50    +0.76%
- Closed. Currency in USD ( Disclaimer )
After Hours
65.83
-0.04
-0.06%
- Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,513,874
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 64.98 - 66.10
Incyte 65.87 +0.50 +0.76%

Incyte Corporation Company Profile

 
Get an in-depth profile of Incyte Corporation, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

2524

Equity Type

ORD

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Contact Information

Address 1801 Augustine Cut-Off
Wilmington, 19803
United States
Phone 302 498 6700
Fax -

Top Executives

Name Age Since Title
Jean-Jacques Bienaime 68 2015 Independent Director
Paul J. Clancy 59 2015 Independent Director
Julian Charles Baker 54 2001 Independent Lead Director
Edmund P. Harrigan 69 2019 Independent Director
Katherine A. High 70 2020 Independent Director
Jacqualyn A. Fouse 61 2017 Independent Director
Otis W. Brawley 62 2021 Independent Director
Susanne Schaffert 56 2022 Independent Director
Herve Hoppenot 63 2014 CEO & Chairman
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

INCY Comments

Write your thoughts about Incyte Corporation
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Alex Crypto
Alexreturn Mar 22, 2023 2:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Great news today, a clear buy
mdm lock
mdm lock Nov 04, 2022 9:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mazen Talal
Mazen Talal Sep 22, 2021 1:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
To da moon
Sadiq Y Lukeman
Sadiq Y Lukeman Aug 03, 2021 10:23AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
not working for me
Handy Arias
Handy Arias Aug 03, 2021 7:07AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
antes Arias Santi Arias
Pozz Tou Ca
Pozz Tou Ca May 07, 2021 11:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Google play Khmer🌟
Ali Daher
Ali Daher Mar 24, 2021 6:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why is this guy down?
Mohamed Mohamed
Mohamed Mohamed Feb 19, 2021 6:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What is going on this stock? It has been dipping with no limit?!
Farxiya Biime
Farxiya Biime Feb 19, 2021 6:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
asc
Joey De Guzman
Joey De Guzman Aug 04, 2020 10:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
beat Earnings, why down?
Şahin Oktay
Şahin Oktay Apr 26, 2020 4:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Turkish biotechnology company produces RTALB diagnostic kit. Its products are in demand in 15 countries. The company has exported more than 2 million kits in the past month.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email